In three previous blog posts, we have discussed recent inventorship issues surrounding Artificial Intelligence (“AI”) and its implications for life sciences innovations – focusing specifically on scientist Stephen Thaler’s attempt to obtain a patent for an invention created by his AI system called DABUS (“Device for Autonomus Bootstrapping of Unified Sentence). Most recently, we considered Thaler’s appeal of the September 3, 2021 decision out of the Eastern District of Virginia, which ruled that under the Patent Act, an AI machine cannot qualify as an “inventor.” Continuing this series, we now consider the USPTO’s recently filed opposition to Thaler’s appeal.

In its opposition brief, the USPTO argued that under the “plain language Congress chose to incorporate in the Patent Act,” only a human being can be considered an “inventor.” The USPTO first noted that the definitions of “inventor” and “joint inventor” under the Patent Act both unequivocally refer only to an “individual” or “individuals.” For example, “inventor” is defined under the Act as “the individual or, if a joint invention, the individuals collectively who invented or discovered the subject matter of the invention.”

While the Patent Act does not explicitly define the term “individual,” the USPTO argued that in other instances where the term is not explicitly defined, courts have interpreted Congress’s use of the term “individual” in a given statute as denoting a “human being,” as opposed to other things. The USPTO provided the example of Mohamad v. Palestinian Auth., a 2012 case in which the Supreme Court evaluated whether Congress’s use of the term “individual in the Torture Victim Protection Act (“TVPA”) could be construed to include an “organization.” There, the Court quoted from several well-known dictionaries and considered the use of the term in “everyday parlance,” to determine that the ordinary meaning of the term “individual” refers only to a human being or natural person. The Court in Mohamad also referred to the Dictionary Act, 1 U.S.C. § 1, which provides that the legislative use of the term “individual” denotes something separate and apart from non-human beings.

The USPTO argued that the Supreme Court’s analysis in Mohamad is equally applicable to the Patent Act as it is to the TVPA. For example, the term “individual” is used in the Patent Act as a noun, just as it is in the TVPA. And, according to the USPTO, just as the Mohamad Court recognized “no one…refers in normal parlance to an organization as an ‘individual,’” it is equally true that “no one… refers in normal parlance” to a machine or collection of source code as an “individual.” Further, the USPTO pointed out that the Dictionary Act applies not only to the TVPA, but to all congressional enactments – including the Patent Act.

Though the Supreme Court’s opinion in Mohamad acknowledges that Congress is free to give the term “individual” a “broader or different meaning,” such “broader” construction by a court requires some affirmative “indication [that Congress] intended such a result.” Here, the USPTO argues that Thaler has never pointed to any textual evidence that Congress intended a broader meaning for the term. The USPTO argues that Thaler has only put forth non-textual policy arguments. For example, Thaler argues that denying inventorship to AI would place the United States behind “other countries [that] are promoting the progress of science,” and would amount to “adopt[ing] luddism.” However, according to the USPTO, these policy considerations cannot overcome the plain meaning of the text.

We will continue to monitor this appeal, as it has important implications for life sciences companies employing AI technologies, particularly given the low probability that Congress will act on this issue in the short term.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Anisha Shenai-Khatkhate Anisha Shenai-Khatkhate

Anisha Shenai-Khatkhate is an associate in the Litigation Department. She is a commercial litigator with a particular emphasis on false advertising and consumer class actions, copyright disputes, and related intellectual property litigation. Anisha has experience representing and advising clients in a wide array…

Anisha Shenai-Khatkhate is an associate in the Litigation Department. She is a commercial litigator with a particular emphasis on false advertising and consumer class actions, copyright disputes, and related intellectual property litigation. Anisha has experience representing and advising clients in a wide array of industries including consumer products, music and entertainment, publishing, telecommunications, fashion and sports.

Anisha is an editor of and a frequent author for Proskauer’s advertising law blog, Proskauer on Advertising.

Prior to joining Proskauer, Anisha earned a B.A. in Neurobiology from Harvard University, and J.D. from Columbia Law School. While at Columbia, Anisha interned at Volunteer Lawyers for the Arts, helping to provide pro bono legal services to New York artists and arts organizations. She also served as an articles editor of the Columbia Science and Technology Law Review, and was the recipient of Columbia Law School’s Emil Schlesinger Labor Law Prize, awarded annually to the student most proficient in the subject of labor law.

Photo of Baldassare Vinti Baldassare Vinti

Baldassare (“Baldo”) Vinti heads Proskauer’s Intellectual Property Litigation Group.

Baldo’s practice focuses on litigating patent, false advertising, trade secret, life sciences, trademark and contractual matters in federal and state courts and before the International Trade Commission. He is a seasoned trial attorney responsible…

Baldassare (“Baldo”) Vinti heads Proskauer’s Intellectual Property Litigation Group.

Baldo’s practice focuses on litigating patent, false advertising, trade secret, life sciences, trademark and contractual matters in federal and state courts and before the International Trade Commission. He is a seasoned trial attorney responsible for all aspects of litigation, including Markman hearings, appeals before the Federal Circuit, case preparation and strategy, depositions, motion practice, and settlement negotiations. He has represented clients in high-stakes matters involving a broad range of technologies, including medical devices, diagnostics, immunoassays, prosthetics, pharmaceuticals, dental implants, electronic medical records systems, encryption technology, wound dressings, digital video compression, electronic book delivery and security systems, mobile media technologies, navigation and location-based services, bandwidth management, bar code scanning, lasers , and other technologies. Baldo has represented numerous major corporations, including Arkema S.A., British Telecommunications PLC, Church & Dwight Co., Inc., Henry Schein, Inc., Maidenform Brands Inc., Mitsubishi Electric Corp., Ossur North America Inc., Panasonic Corp., Sony Corp., Welch Foods, Inc., and Zenith Electronics LLC.

In addition, Baldo regularly handles transactional work, including intellectual property due diligence, licensing, intellectual property structural transactions, patentability studies, infringement/non-infringement opinions, and client counseling in intellectual property matters.

Baldo is an author and frequent commentator on patent issues pertaining to medical devices and a host of other intellectual property topics, and has been quoted in the National Law Journal, Bloomberg BNA, Law360, Westlaw Journal and Inside Counsel magazine. He is also a regular contributor of articles published in Medical Product Outsourcing magazine that deal with the medical device industry.

Baldo served as a judicial intern for Hon. John E. Sprizzo of the United States District Court for the Southern District of New York and for Hon. Charles A. LaTorella of the New York Supreme Court.